News
Videos
Conferences
Events
Resources
Subscribe

|Videos|October 23, 2020

Outside of Treatment in Metastatic Breast Cancer

Author(s)Kristie L. Kahl

Episodes in this series

Kristie L. Kahl and Jamil Rivers

EP. 1 Treatment for Metastatic Breast Cancer

Kristie L. Kahl and Jamil Rivers

EP. 2 Joining a Clinical Trial

EP. 3 Addressing Disparities in Metastatic Breast Cancer

EP. 3 Addressing Disparities in Metastatic Breast Cancer

Kristie L. Kahl and Kate Watson

EP. 4 Outside of Treatment in Metastatic Breast Cancer

EP. 5 Talking with Your Family About Metastatic Breast Cancer

EP. 5 Talking with Your Family About Metastatic Breast Cancer

Newsletter

Stay up to date on cancer updates, research and education

Related Content

"FDA" text.

FDA Approves Enhertu Plus Perjeta in Advanced HER2+ Breast Cancer

December 15th 2025

Inluriyo and Verzenio helped patients with ER+/HER2– advanced breast cancer stay on treatment longer without their disease worsening vs standard therapy.

Inluriyo/Verzenio Extends Treatment Benefit in ER+/HER2– Breast Cancer

ByJason Broderick

December 12th 2025

Enhertu and Perjeta led to better quality-of-life and less side effects than standard-of-care among patients with HER2+ advanced or metastatic breast.

Enhertu/Perjeta Combo Enhances Quality of in HER2+ Advanced Breast Cancer

December 11th 2025

Inluriyo, an oral therapy for ER+, HER2– metastatic breast cancer with ESR1 mutations, offers a new treatment option after prior endocrine therapy.

FDA Approves Inluriyo for ER+, HER2– Metastatic Breast Cancer

BySpencer Feldman

September 25th 2025

Image of women with pink cap.

A Patient Guide to Understanding HER2-Positive Breast Cancer

BySpencer Feldman

September 19th 2025

Trending on CURE

Given Months to Live, She’s Now a Five-Year Glioblastoma Survivor

Tecvayli With Darzalex Could Be ‘Truly Transformative’ in Multiple Myeloma

First U.S. Patient Treated With Alveltamig for Small Cell Lung Cancer

My Three-Time Cancer Journey

How CAN-3110 Works to Treat Glioblastoma